ArticlePain and therapy2025
Synergistic Effects of Basivertebral Nerve Ablation Plus Schroth Therapy for Adult Scoliosis: A Multicenter Propensity-Matched Cohort Study.
Article in Pain and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vertebrogenic Low Back Pain and Basivertebral Nerve Ablation: A Review of Mechanisms, Imaging-Driven Selection, and Clinical Outcomes.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSchroth therapy improves outcomes in mild degenerative scoliosis but may be insufficient for patients with vertebrogenic pain linked to vertebral endplate changes. Basivertebral nerve ablation (BVNA) is a novel intervention that may provide additional benefit in these cases.
methodsThis retrospective, propensity score-matched cohort study included adults aged ≥ 18 years with idiopathic or degenerative scoliosis (Cobb angle ≥ 20°) and vertebrogenic pain, treated between January 1, 2020 and January 31, 2024, across two major healthcare systems. A subset received BVNA between December 5, 2022 and December 5, 2024. Propensity score matching was performed 1:1 for age, sex, body mass index, baseline disability and pain scores, and prior therapy sessions, yielding 44 matched patients (22 per group). The primary outcome was ≥ 15-point improvement in Oswestry Disability Index (ODI) at 12 months. Secondary outcomes included ≥ 3-point pain reduction, opioid and health-resource utilization, and complications.
resultsAmong 76 patients (mean [standard deviation] age 68.8 [14.8] years; 82.9% female), 44 were included in the matched analysis. At 12 months, patients receiving Schroth therapy plus BVNA achieved greater ODI improvement (mean change - 22.3 vs - 15.1; P = 0.03) and were more likely to reach ≥ 15-point ODI improvement (81.8% vs 59.1%; OR 2.58 [95% CI 1.01-6.60]; P = 0.048). Opioid use declined more in the BVNA group (- 37% vs - 14%, P = 0.037), with progressive MEDD reduction (19 → 10 mg) compared with stable use in the Schroth-only group (17 → 17 mg; group × time P = 0.003). Rates of subsequent pain procedures (81.8% vs 13.6%, P < .001) and ER visits for chronic back pain (63.6% vs 9.1%, P = 0.0004) were higher for Schroth-only patients. No complications were reported.
conclusionIn adults with scoliosis and vertebrogenic pain, combining BVNA with Schroth therapy was associated with superior outcomes at 12 months compared with Schroth therapy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.